Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (NASDAQ: RXRX) announced a Board‑approved leadership transition effective January 1, 2026. Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and Board member, will become CEO and President while remaining on the Board. Co‑founder Chris Gibson, Ph.D. will transition from CEO to Chairman of the Board. Rob Hershberg, MD/Ph.D., current Chairman, will become Vice‑Chairman and Lead Independent Director. The Board cited continuity and execution as goals for advancing the OS platform, pipeline readouts, and commercialization priorities.
Recursion (Nasdaq: RXRX) announced participation in two upcoming investor conferences in November 2025. The company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and at the Jefferies Global Healthcare Conference London on Tuesday, November 18, 2025. Webcasts will be available in the events section of Recursion's investor relations website at ir.recursion.com.
Recursion (Nasdaq: RXRX) will report third quarter 2025 business updates and financial results on Wednesday, November 5, 2025 before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube channels. Investors, analysts, and the public can submit questions in advance via the company’s online form at the provided link.
Recursion (NASDAQ:RXRX), a clinical stage TechBio company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Citi 2025 BioPharma Back to School Conference on September 3 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Investors can access the webcasts through Recursion's investor relations website at ir.recursion.com.
Recursion (NASDAQ:RXRX) reported Q2 2025 financial results and business updates. The clinical-stage TechBio company achieved a $7 million milestone payment from Sanofi and provided updates on key clinical programs. Revenue reached $19.2 million, up from $14.4 million in Q2 2024, while net loss widened to $171.9 million from $97.5 million year-over-year.
The company highlighted progress in its clinical pipeline, including REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor). Cash position stood at $533.8 million, with runway expected into Q4 2027. Recursion continues advancing partnerships with Sanofi, Roche/Genentech, Bayer, and Merck KGaA, while expanding its Recursion OS 2.0 platform capabilities.
The company announced a restructuring plan with expected costs of $9.3 million for 2025.Recursion (NASDAQ:RXRX), a clinical stage TechBio company, will release its Q2 2025 financial results on Tuesday, August 5, 2025, before market open.
The company will host a live earnings call at 8:00 AM ET on the same day, which will be broadcasted across multiple social media platforms including X (formerly Twitter), LinkedIn, and YouTube. Stakeholders can submit their questions through a provided online form.
Recursion (NASDAQ: RXRX) has acquired full rights to REV102, a potential first-in-class oral ENPP1 inhibitor program, and an associated backup molecule from Rallybio (NASDAQ: RLYB) for treating hypophosphatasia (HPP). The acquisition aims to develop the first oral disease-modifying treatment for HPP, a rare genetic disorder.
Recursion plans to leverage its Recursion OS platform to accelerate the development of this preclinical asset. The program represents a significant advancement in HPP treatment, as current therapies have limited accessibility. The collaboration combined Rallybio's expertise in HPP research with Recursion's AI/experimental platform capabilities.
Recursion (NASDAQ: RXRX), a clinical stage TechBio company, has announced its upcoming participation in two major investor conferences in May 2025. The company will be presenting at the Bank of America 2025 Health Care Conference on Tuesday, May 13, and the JP Morgan Global Technology, Media and Communications Conference on Thursday, May 15. Interested parties can access the webcasts through Recursion's Investor Relations website at ir.recursion.com.